Document is current
Any future updates will be listed below
-
Authors
Goswami, Sangam Giri
Gupta, Pragya
Arvinden, V. R.
Bhargava, Nupur
Iyer, Aditya Ramdas
Saravanakumar, Vinodh
Yadav, Poonam
Jha, Somesh K.
Singh, Shivani
Kumar, Ajay
Singh, Praveen
Gunda, Padma
Jain, Suman
Mehta, Pallavi
Nakamura, Yukio
Kurita, Ryo
Bajaj, Avinash
Ramalingam, Sivaprakash https://orcid.org/0009-0002-9205-2547
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 15 August 2025
First Online: 21 December 2025
Declarations
:
: The Mobilized and cryopreserved human peripheral blood samples were obtained from SCD and BT patient donors with prior ethics committee approval by CSIR-Institute of Genomics and Integrative Biology- Institutional Human Ethics Committee (IHEC) on 08/02/2018; Project number: CSIR-IGIB/IHEC/2017–18/12; Project name: Generation of naturally occurring beneficial HPFH mutations using CRISPR-Cas9 based targeted genome editing to reactivate fetal hemoglobin: A strategy for treating β-hemoglobin disorders. TSCS-1112018; 2020–001-EMP-28; RCCIRC/IRB-BHR/99/201). The patients or their guardians/legally authorized representatives provided written informed consent for the use of samples. The use of NBSGW mice was approved by CSIR-Institute of Genomics and Integrative Biology-Institutional Animal Ethics Committee (IAEC) on 24/04/2022; Project number: CSIR-IGIB/IAEC/7/24/April2022; Project name: Generation of naturally occurring beneficial HPFH mutations using CRISPR-Cas9 based targeted genome editing to reactivate fetal hemoglobin: A strategy for treating β-hemoglobin disorders.
: Not Applicable.
: For the use of HUDEP-2 cell line, the original source (RIKEN) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent.
: The authors declare that they have no conflict of interest.
